2206 GMT - The rise in China's birth rate should help improve sentiment toward The a2 Milk Company's major infant-formula market, Morgan Stanley analysts say. They warn that tangible impacts on industry volumes are expected to lag the recovery in birth rates, but nonetheless call it out as a likely positive for the Australia-listed producer. They tell clients in a note that China's latest births data implies a 5.8% on-year rise in the number of new babies in 2024. MS has an equal-weight rating and A$5.90 target price on the stock, which is at A$5.81 ahead of the open. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
January 19, 2025 17:06 ET (22:06 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.